US4497799A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptide carcinostatic agent
Assignee: Suntory Ltd
•
Filing: 1981-11-09
•
Granted: 1985-02-05
•
Expires: 2001-11-09
Abstract
Abstract A
Inventors
- 👤 Hajime Yoshizumi
- 👤 Kumao Toyoshima
- 👤 Akira Hakura
- 👤 Toshihiro Nakanishi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:39
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/415; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/26
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
97 words
A method for inhibiting growth of transplanted tumors in mice comprising: administering to said mice an antitumor effective amount of a composition comprising: (a) a polypeptide having the formula: ##SPC3## wherein the abbreviations, Ala, Arg, Asn, Cys, Gln, Gly, Leu, Lys, Phe, Pro, Ser, Thr, Tyr and Val represent the L-form residues of alanine, arginine, asparagine, 1/2 cysteine, glutamine, glysine, leucine, lysine, phenylalanine, proline, serine, threonine, tyrosine, and valine, respectively; and the designation "═" represents --S--S--bond and the arabic numbers adjacent to the amino acid cords depict the amino acid sequential arrangement as enumerated from the N-terminal.
Claim 2
Independent Claim
97 words
A method for inhibiting growth of transplanted tumors in mice comprising: administering to said mice an antitumor effective amount of a composition comprising: (a) a polypeptide having the formula: ##SPC3## wherein the abbreviations, Ala, Arg, Asn, Cys, Gln, Gly, Leu, Lys, Phe, Pro, Ser, Thr, Tyr and Val represent the L-form residues of alanine, arginine, asparagine, 1/2 cysteine, glutamine, glysine, leucine, lysine, phenylalanine, proline, serine, threonine, tyrosine, and valine, respectively; and the designation "═" represents --S--S--bond and the arabic numbers adjacent to the amino acid cords depict the amino acid sequential arrangement as enumerated from the N-terminal.
Claim 3
Dependent Claim
27 words
The method according to claim 1, wherein said polypeptide is administered in an amount of from 0.3 to 1.0 mg per kg of body weight per day.
Claim 4
Dependent Claim
13 words
The method according to claim 1, wherein said tumor is a sarcoma tumor.
Claim 5
Dependent Claim
15 words
The method according to claim 1, wherein said tumor is an EAC (Ehrlich ascites carcinoma).
Claim 6
Dependent Claim
13 words
The method according to claim 1, wherein said tumor is a leukemia tumor.
References Cited (Backward Citations)
JPS5550897A
Cited
US4287185A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-02-05 | 1988-08-06 | 1989-02-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-02-05 | 1992-08-06 | 1993-02-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-02-05 | 1996-08-06 | 1997-02-05 | $7700.00 | Window Closed / Lapsed |